Publications by authors named "T Gudmundsdottir"
Purpose: Childhood cancer survivors are at the risk of developing subsequent colorectal cancers (CRCs), but the absolute risks by treatment modality are uncertain. We quantified the absolute risks by radiotherapy treatment characteristics using clinically accessible data from a Pan-European wide case-control study nested within a large cohort of childhood cancer survivors: the PanCareSurFup Study.
Methods: Odds ratios (ORs) from a case-control study comprising 143 CRC cases and 143 controls nested within a cohort of 69,460 survivors were calculated.
Article Synopsis
- Radiation exposure to bone tissue in childhood cancer survivors is linked to an increased risk of bone cancer, with a stronger correlation observed for doses above 1 Gy.
- A study of 228 cases and controls from 12 European countries found significant odds ratios for bone cancer related to radiation doses of 1-9 Gy and high cumulative doses of alkylating agents.
- The findings highlight the need to revise clinical follow-up guidelines for childhood cancer survivors due to the increased risks, especially for specific chemotherapy drugs like procarbazine, ifosfamide, and cyclophosphamide.
Article Synopsis
- Survivors of childhood cancer, particularly those who had Hodgkin lymphoma (HL), are at a significantly increased risk of developing non-Hodgkin lymphoma (NHL) and other subsequent primary lymphomas (SPLs), as shown in a study involving over 69,000 survivors from 12 European countries.
- The study found that childhood cancer survivors had a 60% higher risk of SPLs compared to the general population, with the risk being notably higher for those treated for HL, Wilms tumor, leukemia, and bone sarcoma.
- While chemotherapy increased the risk of NHL significantly, radiotherapy did not have the same effect; however, survivors of childhood cancer should be aware of their elevated risk for NHL, especially
Background: Survivors of childhood cancer are at risk of subsequent primary malignant neoplasms (SPNs), but the risk for rarer types of SPNs, such as oral cancer, is uncertain. Previous studies included few oral SPNs, hence large-scale cohorts are required to identify groups at risks.
Methods: The PanCareSurFup cohort includes 69,460 5-year survivors of childhood cancer across Europe.
Impact of era of diagnosis on cause-specific late mortality among 77 423 five-year European survivors of childhood and adolescent cancer: The PanCareSurFup consortium.
Int J Cancer
February 2022
Late mortality of European 5-year survivors of childhood or adolescent cancer has dropped over the last 60 years, but excess mortality persists. There is little information concerning secular trends in cause-specific mortality among older European survivors. PanCareSurFup pooled data from 12 cancer registries and clinics in 11 European countries from 77 423 five-year survivors of cancer diagnosed before age 21 between 1940 and 2008 followed for an average age of 21 years and a total of 1.
View Article and Find Full Text PDF